JP2019512222A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512222A5
JP2019512222A5 JP2018546577A JP2018546577A JP2019512222A5 JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5 JP 2018546577 A JP2018546577 A JP 2018546577A JP 2018546577 A JP2018546577 A JP 2018546577A JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5
Authority
JP
Japan
Prior art keywords
polypeptide
terminal
mhc
amino acid
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512222A (ja
JP7372036B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020480 external-priority patent/WO2017151940A2/en
Publication of JP2019512222A publication Critical patent/JP2019512222A/ja
Publication of JP2019512222A5 publication Critical patent/JP2019512222A5/ja
Application granted granted Critical
Publication of JP7372036B2 publication Critical patent/JP7372036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546577A 2016-03-03 2017-03-02 T細胞調節多量体ポリペプチド及びその使用方法 Active JP7372036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303268P 2016-03-03 2016-03-03
US62/303,268 2016-03-03
PCT/US2017/020480 WO2017151940A2 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019512222A JP2019512222A (ja) 2019-05-16
JP2019512222A5 true JP2019512222A5 (enExample) 2020-04-09
JP7372036B2 JP7372036B2 (ja) 2023-10-31

Family

ID=59743280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546577A Active JP7372036B2 (ja) 2016-03-03 2017-03-02 T細胞調節多量体ポリペプチド及びその使用方法

Country Status (9)

Country Link
US (2) US20190046648A1 (enExample)
EP (1) EP3423078A4 (enExample)
JP (1) JP7372036B2 (enExample)
KR (1) KR20180132070A (enExample)
CN (1) CN109414498A (enExample)
AU (1) AU2017225787B2 (enExample)
CA (1) CA3014466A1 (enExample)
IL (1) IL261402A (enExample)
WO (1) WO2017151940A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
CN111886241A (zh) * 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
EP3796930A4 (en) * 2018-05-23 2022-05-04 Gritstone bio, Inc. IMMUNE CHECKPOINT INHIBITOR KO-EXPRESSION VECTORS
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ, インコーポレイテッド T細胞調節抗原提示ポリペプチド及びその使用方法
AU2020282736B2 (en) * 2019-05-29 2025-10-30 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CA3139968A1 (en) * 2019-06-05 2020-12-10 Peter Peizhi Luo Anti-cd137l antibodies and methods of using same
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
WO2021055594A1 (en) * 2019-09-20 2021-03-25 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
TW202233694A (zh) * 2021-02-07 2022-09-01 大陸商正大天晴藥業集團股份有限公司 雙特異性抗體
WO2024088404A1 (en) * 2022-10-28 2024-05-02 Fbd Biologics Limited Engineered 4-1bbl variants and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
WO1998030693A2 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
AU2002322211A1 (en) * 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
AU2002363354A1 (en) * 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
AU2002366433A1 (en) * 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US6911321B2 (en) * 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
ES2601327T3 (es) * 2006-01-23 2017-02-14 Novozymes A/S Polipéptidos con actividad de lipasa y polinucleótidos que codifican los mismos
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CN102898504B (zh) * 2012-10-23 2014-08-06 中国农业大学 抗氧化活性合成肽及其用途
AU2014291961B2 (en) 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
PT3480213T (pt) * 2014-06-18 2020-02-04 Albert Einstein College Medicine Polipéptidos syntac e utilizações dos mesmos
US11111284B2 (en) * 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
US11505591B2 (en) * 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019516665A5 (enExample)
JP2019522466A5 (enExample)
JP2019522465A5 (enExample)
JP2020511949A5 (enExample)
JP2022515330A5 (enExample)
JP2022536581A5 (enExample)
JP6923714B2 (ja) Mhcクラスii拘束性mage−a3を認識するt細胞受容体
IL308851B2 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
JP2025063029A5 (enExample)
JP2020074776A5 (enExample)
JP2017527272A5 (enExample)
IL272085B2 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2017509335A5 (enExample)
JP2017519491A5 (enExample)
JP2021527700A5 (enExample)
JP2019514358A5 (enExample)
JP2015535816A5 (enExample)
JP2017512063A5 (enExample)
JP2015525217A5 (enExample)
RU2010100913A (ru) Слитые белки rage
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
JP2018519803A5 (enExample)
JP2022522405A5 (enExample)
IL309260B1 (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
JP2024512470A5 (enExample)